Highest-materiality recent filing
MVLS fell below $50M for 30 consecutive business days as of March 31, 2026.
Vesicor Therapeutics appoints Michael Tolentino as CEO; Luo Feng becomes CSO
Michael Tolentino, M.D., appointed CEO of Vesicor Therapeutics, the de-SPAC target of Black Hawk Acquisition (Nasdaq: BKHA, BKHAU, BKHAR), effective March 17, 2026.
Black Hawk Acquisition reports ~70% share redemption; $51M withdrawn from trust
Holders of 4,775,923 ordinary shares redeemed at $10.68/share, removing ~$51.0M from trust account.
Black Hawk Acquisition shareholders approve extension to Dec 2026; ~$51M redeemed
Shareholders approved extension of business combination deadline to Dec 22, 2026, with up to 18 monthly extensions at $150k each.
Black Hawk SPAC enters $70M merger with Vesicor Therapeutics; p53 cancer therapy focus
Total equity value $70M; Aggregate Merger Consideration = $70M divided by Redemption Price.
Black Hawk Acquisition closes IPO of 6.9M units at $10/unit, raising $69M gross
IPO of 6,900,000 units at $10.00 each; each unit consists of one ordinary share and one right to receive one-fifth of a share.
Black Hawk Acquisition closes upsized $69M SPAC IPO; $69.3M placed in trust
Sold 6,900,000 units at $10/unit, gross proceeds $69M; underwriter option for up to 1,035,000 additional units.
On April 29, 2025, Black Hawk Acquisition Corporation (the “Company”) reported the death of Brandon Miller, a member of the Company’s board of directors (the “Board”) and the Chairperson of the Audit Committee.
On April 22, 2024, the board of directors (the “Board”) of Black Hawk Acquisition Corporation (the “Company”) appointed Jonathan Ginsberg as the Chief Operating Officer and a director of the Company, effective immediately.
On April 22, 2024, the board of directors (the “Board”) of Black Hawk Acquisition Corporation (the “Company”) appointed Jonathan Ginsberg as the Chief Operating Officer and a director of the Company, effective immediately.
Max materiality 0.80 · Median 0.40 · Most common event other_material